Thailand Healthcare Cancer Treatment
Thailand’s expanding publicly funded cancer-care system presents growing opportunities for United States companies offering advanced diagnostics, genetic testing, vaccines, radiotherapy systems, robotic-assisted surgery, oncology treatments, digital health solutions, and related training and support services.
Managed by Thailand’s National Health Security Office (NHSO), the Universal Coverage Scheme (UCS) – widely known as the “Gold Card” scheme – provides eligible Thai citizens with cancer screening and treatment services at no cost.
According to the Universal Health Coverage data, 633,866 cancer patients received treatment under the program in 2025, up 77 percent from 357,737 in 2021. During the same five-year period, outpatient visits rose from 1.68 million to 3.52 million, while inpatient visits increased from 490,519 to 627,165.
The mortality rate among cancer patients covered by the system declined significantly from 20.3 percent in 2021 to 11.8 percent in 2025. These results reflect both expanded access to cancer services and enhanced quality of care for patients throughout Thailand.
NHSO data further indicated that of the 633,866 cancer patients receiving services under the UCS in 2025, 247,608 patients (39.1%) were newly diagnosed cases, while 386,258 patients (60.9%) were continuing treatment cases.
Most Common Cancers Among Male Patients:
- Colon cancer: 24,144 patients
- Liver and intrahepatic bile duct cancer: 21,705 patients
- Prostate cancer: 17,343 patients
- Lung and bronchial cancer: 16,717 patients
Most Common Cancers Among Female Patients:
- Breast cancer: 93,495 patients
- Colon cancer: 24,643 patients
- Cervical cancer: 22,084 patients
- Lung and bronchial cancer: 14,256 patients
Key Cancer Care Initiatives under the Universal Coverage Scheme
- 2013: Introduced stem cell transplantation for patients with leukemia and lymphoma.
- 2017: Expanded cervical cancer screening services nationwide.
- 2018: Introduced the human papillomavirus (HPV) vaccine for Grade 5 female students and launched colorectal cancer screening.
- 2020: Upgraded cervical cancer screening to HPV DNA testing and piloted home-based chemotherapy services for colorectal cancer patients.
- 2021: Implemented the “Cancer Treatment Everywhere” policy, enabling UCS beneficiaries to receive cancer treatment free of charge at public hospitals nationwide without requiring referral from their registered healthcare facilities.
- 2022: Added BRCA1 and BRCA2 gene testing for high-risk breast cancer patients and immediate relatives carrying identified mutations, while expanding screening services for precancerous lesions and oral cancer.
- 2024: Expanded benefits to include breast cancer screening through mammograms and ultrasonography, proton beam radiation therapy, and robotic-assisted surgery.
- 2025: Upgraded the HPV vaccine to the nine-valent formulation and introduced transportation support for patients traveling to receive specialized cancer services.
- 2026: Added advanced radiotherapy services using 3D-printed brachytherapy devices and magnetic resonance linear accelerator (MR Linac) treatment for eligible patients requiring specialized cancer care.
The substantial growth in cancer care utilization, coupled with declining mortality, highlights Thailand’s sustained investment in early detection, nationwide access, and advanced treatment. As the UCS continues to expand its benefits and adopt sophisticated medical technologies, U.S. companies are well-positioned to support Thailand’s demand for innovative cancer-screening, diagnostic, treatment, and patient-care solutions.
For further information, please contact the U.S. Commercial Service in Bangkok, Thailand at Kornluck.tantisaeree@trade.gov